aspirin has been researched along with Heart Septal Defects, Ventricular in 10 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Heart Septal Defects, Ventricular: Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to compare preoperative and postoperative conditions of GMP-140 concentration, the aggregation and activation of platelets in congenital heart disease patients undergoing transcatheter closure of atrial septal defects (ASDs) or ventricular septal defects (VSDs), and the appropriate dose of aspirin of patients after transcatheter closure." | 9.19 | Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects. ( Long, SC; Pan, G; Xie, ZF; Xu, XP; Zhang, Y; Zhang, ZW, 2014) |
| "The aim of this study is to compare preoperative and postoperative conditions of GMP-140 concentration, the aggregation and activation of platelets in congenital heart disease patients undergoing transcatheter closure of atrial septal defects (ASDs) or ventricular septal defects (VSDs), and the appropriate dose of aspirin of patients after transcatheter closure." | 5.19 | Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects. ( Long, SC; Pan, G; Xie, ZF; Xu, XP; Zhang, Y; Zhang, ZW, 2014) |
| " Additionally, he had undergone an aortic root dilatation and aortic valve replacement at the age of 10 because of progression of aortic and supra-aortic stenosis and had received chronic anticoagulation and antiplatelet therapy with warfarin and aspirin, respectively." | 4.02 | Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease. ( Ifuku, T; Nishiguchi, T, 2021) |
| "Intermittent left bundle branch block is a conduction disturbance that has been described to be associated with myocardial bridges and cardiac memory." | 1.51 | Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report. ( Ibarrola, M, 2019) |
| "Two patients with perimembranous ventricular septal defects (VSDs) and inlet extension have undergone uncomplicated transcatheter device closure using the Amplatzer membranous VSD device." | 1.33 | Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect. ( Hijazi, ZM; Yip, WC; Zimmerman, F, 2005) |
| " There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17." | 1.32 | Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms. ( Cook, JC; Gupta, U; Hurtt, ME; Tassinari, MS, 2003) |
| "Both COX inhibitors were toxic to dams in the highest doses evaluated, which caused a significantly greater incidence of intrauterine growth retardation and developmental variations." | 1.32 | Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats. ( Burdan, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ifuku, T | 1 |
| Nishiguchi, T | 1 |
| Hage, A | 1 |
| Jacques, F | 1 |
| Chetaille, P | 1 |
| Bourdages, M | 1 |
| Cloutier, K | 1 |
| Perron, J | 1 |
| Houde, C | 1 |
| Ibarrola, M | 1 |
| Pan, G | 1 |
| Xie, ZF | 1 |
| Zhang, Y | 1 |
| Long, SC | 1 |
| Xu, XP | 1 |
| Zhang, ZW | 1 |
| Butera, G | 1 |
| Gaio, G | 1 |
| Carminati, M | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Gupta, U | 1 |
| Cook, JC | 1 |
| Tassinari, MS | 1 |
| Hurtt, ME | 1 |
| Burdan, F | 1 |
| Yip, WC | 1 |
| Zimmerman, F | 1 |
| Hijazi, ZM | 1 |
| Pesonen, E | 1 |
| Thilen, U | 1 |
| Sandström, S | 1 |
| Arheden, H | 1 |
| Koul, B | 1 |
| Olsson, SE | 1 |
| Wilson, RF | 1 |
| Toher, C | 1 |
| Bank, A | 1 |
| Bass, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
1 trial available for aspirin and Heart Septal Defects, Ventricular
| Article | Year |
|---|---|
Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects.
Topics: Adolescent; Adult; Aspirin; Cardiac Catheterization; Female; Heart Septal Defects, Atrial; Heart Sep | 2014 |
9 other studies available for aspirin and Heart Septal Defects, Ventricular
| Article | Year |
|---|---|
Spontaneous Spinal Epidural Hematoma in an Adult Patient with Complex Congenital Heart Disease.
Topics: Adult; Anticoagulants; Aortic Valve Stenosis; Aspirin; Heart Defects, Congenital; Heart Septal Defec | 2021 |
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
Topics: Aspirin; Coronary Vessels; Female; Fibrinolytic Agents; Heart Septal Defects, Ventricular; Heart Val | 2017 |
Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Aspirin; Bundle-Branch Block; Cardiotonic Agents; Compu | 2019 |
Is steroid therapy enough to reverse complete atrioventricular block after percutaneous perimembranous ventricular septal defect closure?
Topics: Anti-Inflammatory Agents; Aspirin; Atrioventricular Block; Cardiac Catheterization; Cardiac Pacing, | 2009 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; | 2003 |
Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats.
Topics: Animals; Aspirin; Body Weight; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; | 2004 |
Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect.
Topics: Aspirin; Cardiac Catheterization; Cardiac Surgical Procedures; Child, Preschool; Drug Therapy, Combi | 2005 |
Transcatheter closure of post-infarction ventricular septal defect with the Amplatzer Septal Occluder device.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Follow-Up Studies; Heart Sep | 2000 |